Impact of Participant Baseline Factors on Exposure-Adjusted Incidence of Treatment-Related Adverse Events During Peanut Oral Immunotherapy
The Journal of Allergy and Clinical Immunology: In Practice · 2025
DOI: 10.1016/j.jaip.2025.09.010 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Melanie Lloyd und 7 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Health Economics and Policy Evaluation Research Group, Cen…. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Desensitization, Immunologic, Allergens, Arachis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: State Government of Victoria, National Health and Medical Research Council, Australasian Society of Clinical Immunology and Allergy.
Themen: Patientensicherheit
Abstract (Originalsprache)
BACKGROUND: Oral immunotherapy (OIT) causes frequent treatment-related adverse events (AEs), particularly during dose escalation, which can cause treatment withdrawal. OBJECTIVE: To determine whether patient characteristics influenced the frequency of treatment-related AEs during dose escalation. METHODS: We obtained data from a multicenter randomized trial (PPOIT-003) involving 201 children aged 1 to 10 years who received probiotic peanut oral immunotherapy (PPOIT), peanut OIT alone (OIT), or placebo. Frequency of AEs was expressed as the exposure-adjusted incidence rate (EAIR). We used multivariable Poisson regression models with interaction terms to explore whether baseline participant factors modified the effect of treatment on EAIR of treatment-related AEs during dose escalation. RESULTS: The EAIR of AE in PPOIT and OIT groups was threefold higher compared with placebo, with no difference comparing PPOIT and OIT (PPOIT vs placebo: rate ratio [RR] = 3.62, 95% CI, 2.92-4.48, P < .001; OIT vs placebo: RR = 3.62, 95% CI, 2.93-4.48, P < .001; and PPOIT vs OIT: RR = 1.00, 95% CI, 0.90-1.10; P = .98). Older children (aged ≥6 years) and females had a higher EAIR in all treatment groups. Allergic sensitivity and preexisting allergic conditions modified the effect of treatment on EAIR (likelihood ratio test all P < .001). Children with a skin prick test result of 15 mm or greater, peanut-specific IgE of 40 kU/L or greater, reaction dose threshold less than 320 mg for peanut protein, or history of asthma, allergic rhinitis, or anaphylaxis were more likely to report frequent treatment-related AEs when receiving PPOIT or OIT, but not placebo. CONCLUSION: Children with higher allergic sensitivity or allergic comorbidities are more likely to experience frequent treatment-related AEs during peanut OIT dose escalation and may benefit from more intensive monitoring and support to optimize treatment success.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Health Economics and Policy Evaluation Research Group, Centre for Medicine Use and Safety, Monash University, Parkville, Victori…
- Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Allergy and Immunology, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia; Department of Paediatrics, Universi…
- Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
- Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia; Allergy Department, Monash Children's Hospit…
- Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
- Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Allergy Department, Monash Children's Hospital, Clayton, Melbourne, Victoria, Australia.
Förderung
- State Government of Victoria
- National Health and Medical Research Council
- Australasian Society of Clinical Immunology and Allergy
Zitieren
APA
Lloyd, M., Ashley, S., Chawla, S. S., Loke, P., Orsini, F., Lozinsky, A. C., Tang, P., & Tang, M. L. K. (2025). Impact of Participant Baseline Factors on Exposure-Adjusted Incidence of Treatment-Related Adverse Events During Peanut Oral Immunotherapy. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2025.09.010
Vancouver
Lloyd M, Ashley S, Chawla SS, Loke P, Orsini F, Lozinsky AC, et al. Impact of Participant Baseline Factors on Exposure-Adjusted Incidence of Treatment-Related Adverse Events During Peanut Oral Immunotherapy. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2025.09.010
BibTeX
@article{Lloyd2025,
author = {Lloyd, Melanie and Ashley, Sarah and Chawla, Sarabnoor Singh and Loke, Paxton and Orsini, Francesca and Lozinsky, Adriana Chebar and Tang, Ping and Tang, Mimi L K},
title = {Impact of Participant Baseline Factors on Exposure-Adjusted Incidence of Treatment-Related Adverse Events During Peanut Oral Immunotherapy},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2025},
doi = {10.1016/j.jaip.2025.09.010}
}
EUVIMED